|Overview||Expression host strains for pETBlue™ and pTriEx™ vectors are lDE3 lysogens that also carry the compatible pLacI plasmid, encoding the lac repressor. The pLacI plasmid confers chloramphenicol resistance and provides enough lac repressor to inhibit transcription from the T7lac promoter in the absence of inducer. The NovaBlue host strain is recommended for initial cloning with pETBlue and pTriEx vectors due to its superior transformation efficiency and high yields of high-quality plasmid DNA.
Note that these strains are not recommended for use with pET, pACYCDuet™, pCDF, pRSF, pCOLADuet™ or pETcoco™ vectors.
.Origami B host strains carry the same trxB/gor mutations as the original Origami strains, except that they are derived from a lacZY mutant of BL21 to enable pecise control of expression levels by adjusting the concentration of IPTG. Thus the Origami B strains combine the desirable characteristics of BL21, Tuner™, and Origami hosts in one strain background. The trxB and gor mutations are selectable on kanamycin and tetracycline, respectively; therefore, these strains cannot be used with the plasmids carrying kanamycin or tetracycline resistance genes. These strains also include the lon and ompT deficiences of BL21, which increase protein stability.
DE3 indicates that the host is a lysogen of λDE3, and therefore carries a chromosomal copy of the T7 RNA polymerase gene under control of the lacUV5 promoter. Such strains are suitable for production of protein from target genes cloned in pET vectors by induction with IPTG.
|Genotype: F– ompT hsdSB (rB– mB–) gal dcm lacY1 ahpC (DE3) gor522::Tn10 trxB pLacI (CamR, KanR, TetR)
This product contains genetically modified organisms (GMO). Within the EU GMOs are regulated by Directives 2001/18/EC and 2009/41/EC of the European Parliament and of the Council and their national implementation in the member States respectively. This legislation obliges MilliporeSigma to request certain information about you and the establishment where the GMOs are being handled. Click here for Enduser Declaration (EUD) Form.
This product is sold for internal research use only. Any commercial use of this product, its components, and/or any derivatives thereof (including but not limited to proteins produced using the product or its components) (together and hereinafter the 'EMD Product') requires signature of a written commercial use agreement with EMD Millipore Corporation or its successor-in-interest. Commercial use shall include but not be limited to: (1) use of the EMD Product to manufacture products for sale to third parties; (2) use of the EMD Product to provide services, information, or data to third parties in exchange for consideration; (3) use of the EMD Product for therapeutic, diagnostic or prophylactic purposes (including as part of a device, chip, assay or other product); or (4) resale of the EMD Product, whether or not such EMD Product is resold for research use. Nothing contained herein shall be deemed to represent or warrant that additional third party rights are not required for use of the EMD Product. Please direct any questions on these use restrictions to: email@example.com.
|Guaranteed efficiency||Guaranteed efficiency: > 2 x 10⁶ cfu/μg|
|Safety Information according to GHS|
|Product Usage Statements|
|Storage and Shipping Information|
|Ship Code||Dry Ice Only|
|Toxicity||Multiple Toxicity Values, refer to MSDS|
|Do not freeze||Ok to freeze|
|Global Trade Identification Number|
Origami™ B(DE3)pLacI Competent Cells - Novagen SDS
|TB009 Competent Cells|
|TB053 Academic and Non-profit Laboratory Assurance Letter|
|TB249 pETBlue™ System Manual|
|TB250 pTriEx™ System Manual|